LEUKOCARE

Leukocare appoints Professor Bernhardt L. Trout to the Scientific Advisory Board

Martinsried/Munich, Germany, May 10, 2022

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced today the appointment of Professor Bernhardt L. Trout, Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, as a member to the Company´s Scientific Advisory Board (SAB). Professor Trout is an internationally renowned, highly experienced professional on sophisticated computational, theoretical, and experimental methods in order to probe complex chemical systems on the molecular level. With the appointment of Professor Trout, Leukocare will further broaden its expertise in machine learning and biopharmaceutical formulation development.

Dr Andreas Seidl, Chief Operating Officer at Leukocare, commented, "We are very proud to welcome Professor Trout to Leukocare's SAB. Drawing on his vast scientific expertise on molecular engineering, he will support our activities in machine learning and prediction of stability to accelerate and enhance the development of stable biopharmaceutical formulations. We very much look forward to our cooperation and scientific exchange."

Professor Trout focuses his research on the development of advanced manufacturing processes and rational tools for formulation and product design, primarily liquid formulations, but also lyophilized formulations. A major aspect of his work relates to the development of both microscopic and macroscopic models to design stable formulations efficiently. Together with colleagues from MIT, he set-up the Novartis-MIT Center for Continuous Manufacturing in 2007 which until 2019 actively pursued the objective of transforming pharmaceutical production.

Leukocare's SAB now comprises of Professor Johannes Buchner, Ph.D., Technical University of Munich, Germany, Professor Paul Dalby, Ph.D., University College London, United Kingdom, Professor Ulrike Protzer, Ph.D., Technical University of Munich, Germany, Professor Theodore Randolph, University of Colorado, Boulder, USA, and Professor Bernhardt. L. Trout, Massachusetts Institute of Technology, USA. The SAB works closely with the scientific management team to help grow the technology strategy portfolio of Leukocare and to advise

on current and future research activities. Further information can be found on the Company's website at www.leukocare.com/who-we-are/scientific-advisory-board.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines expert knowledge of formulation development with bioinformatics and biostatistics.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a bioinformatics based development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs.

Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:
Jacqueline Sutter
Head of Marketing, Communications, and Digital Business
jackie.sutter@leukocare.com
+49 (0) 172 8451334

Rebekka Ströver
Specialist Communications & Marketing
rebekka.stroever@leukocare.com
+ 49 (0) 89 7801 665 14